Further Grant Application


 

TIDMHML 
 
RNS Number : 9866B 
Henderson Morley PLC 
05 November 2009 
 
05 November 2009 
HENDERSON MORLEY PLC 
("Henderson Morley" or the "Company") 
(AIM: HML) 
FURTHER GRANT APPLICATION 
The Board of Henderson Morley plc, the Aim quoted biotechnology company, is 
pleased to announce that it has submitted a joint grant application to the 
Queensland Government Research Industry Partnership Program (RIPP) in order to 
aid the progress  of its the  Cytomegalovirus ("CMV") vaccine development 
programme. 
The grant, which has been written in conjunction with the Queensland Institute 
of Medical Research (QIMR), has been submitted to the RIPP. The RIPP program 
aims to facilitate the development of near to market research projects between 
industry and research organisations. The key objective of the RIPP is to 
facilitate the development of new or improved products processes and systems 
that will achieve a commercial return or deliver a public good within four 
years. 
The grant application has been made as a collaboration between QIMR and 
Henderson Morley, and funding is matched 1:1. Henderson Morley will contribute 
in the form of staff and overhead costs, and will not incur any additional costs 
over existing cash burn and the QIMR will make a similar contribution. 
If successful, the total application will be valued at AUS$2.43 million (GBP 
1.35 million) over a three year period. If the application is successful it is 
anticipated that the Company will be notified by Spring 2010 and the project 
will then begin mid 2010. 
This grant application is supplementary to the Grant Application made to the NIH 
in August 2009. 
Commenting on the grant applications, Chairman of Henderson Morley, Andrew 
Knight said: "This grant application  presents another opportunity for the 
Company to secure non dilutive funding, and we continue to explore all possible 
avenues in order to gain such funding and add value for shareholders. 
"We are very pleased to be collaborating with the world renowned team based at 
QIMR on such an important public health project." 
Professor Rajiv Khanna, Director of the Australian Centre for Vaccine 
development, based in Brisbane, Queensland Commented: "I am pleased a grant 
application has been made. I have previously been awarded a grant from 
the Queensland Government so I am well aware of the importance of this type of 
funding as well as the invaluable non-financial assistance associated with such 
a grant. 
"I am delighted to be working with Henderson Morley. The complementary aspects 
of the Henderson Morley's PREPS and L-particles and the QIMR poly-epitope 
antigen make this a particularly exciting vaccine project with which to be 
involved. 
 
-END- 
 
Enquires 
HENDERSON MORLEY PLC                                                  0121 442 
4600 
Andrew Knight, Chairman 
BISHOPSGATECOMMUNICATIONS LTD                               0207 562 
3350 
Maxine Barnes 
 Gemma O'Hara 
BREWIN DOLPHIN INVESTMENT BANKING                            0113 241 
0126 
Neil Baldwin 
RIVINGTON STREET CORPORATE FINANCE                           0207 562 
3380 
Monisha Varadan 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 STRDZLFBKFBFFBE

Henderson Mrly. (LSE:HML)
過去株価チャート
から 5 2024 まで 6 2024